NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Cannara Biotech Inc. (LOVE.TO) Stock Analysis

Cannara Biotech Inc. (LOVE.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 21, 2026

LOVE.TO

CA$2.02

−CA$0.02 (−0.98%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LOVE.TO with… →

LOVE.TO Key Statistics

As of Oct 21, 2026
Trading
Open
CA$2.04
Previous Close
CA$2.04
Day's Range
2.02–2.05
52-Week Range
1.55–2.37
Volume
5.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.27
Valuation
Market Cap
CA$199.54M
P/E Ratio
18.36
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.93
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.70
EPS (ttm)Profit attributable to each share over the last twelve months.
0.11
Financials (FY)
Revenue (FY)
CA$107.20M+31.14%
Net Income (FY)
CA$13.08M+103.09%
Profit marginThe share of revenue left as profit after all costs and taxes.
9.25%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
98.78M
1-Year Return
+17.44%
Dividend and dates
Earnings Date
November 23, 2026
Avg Volume
45.21K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LOVE.TO closed at CA$2.02, +17.44% over 1 year.

Cannara Biotech Inc. (LOVE.TO) has a market capitalization of CA$199.54M.

In fiscal 2025, LOVE.TO reported revenue of CA$107.20M.

LOVE.TO Stock Return by Calendar Year

Cannara Biotech Inc. (LOVE.TO) return since Jan 2019: what CA$10,000 became

1 year
CA$10,000 CA$11,744
+17.44%
5 years
CA$10,000 CA$139,310
+1,293.10%
Since Jan 2019
CA$10,000 CA$66,230
+562.30%

If you had invested CA$10,000 in Cannara Biotech Inc. (LOVE.TO) at the close on January 14, 2019, the earliest close on record here, it would have been worth CA$66,230 at the close on October 21, 2026: +562.30% in total, +27.56% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+16.09%
2025+135.14%
2024−10.84%
2023+773.68%
2022−29.63%
2021+68.75%
2020−36.00%
2019−59.02%

As of October 21, 2026.

LOVE.TO Revenue and Earnings by Fiscal Year

FY ends August
Fiscal yearRevenueNet incomeNet margin
2025CA$107.20MCA$13.08M12.2%
2024CA$81.75MCA$6.44M7.9%
2023CA$57.26MCA$6.95M12.1%
2022CA$35.84MCA$2.31M6.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$107.20MCA$47.10MCA$21.77MCA$13.08M12.2%
2024CA$81.75MCA$29.79MCA$8.04MCA$6.44M7.9%
2023CA$57.26MCA$27.23MCA$12.02MCA$6.95M12.1%
2022CA$35.84MCA$17.33MCA$4.98MCA$2.31M6.4%

Annual figures as reported, in the company's reporting currency. As of August 31, 2025.

LOVE.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricLOVE.TODrug Manufacturers - Specialty & Generic medianvs median
P/E18.3620.3110% below
P/S ratio1.702.1019% below
Profit margin9.25%−8.14%17.4 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Cannara Biotech Inc. (LOVE.TO) is capitalised at CA$199.54M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 452 employees.

Over the past 52 weeks the price has ranged from CA$1.55 to CA$2.37. The most recent close on file for LOVE.TO is CA$2.02, dated October 21, 2026. That is −CA$0.02 (−0.98%) against the previous close. The latest close sits 30.32% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$107.20M. That is +31.14% against the prior fiscal year, when revenue was CA$81.75M. The same year closed with net income of CA$13.08M. That is +103.09% against the prior fiscal year. Profit margin runs at 9.25%. That is 17.4 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 0.11.

Across the 4 fiscal years on file, revenue moves from CA$35.84M in 2022 to CA$107.20M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 18.36. That is 9.62% below the Drug Manufacturers - Specialty & Generic median of 20.31. The forward P/E on file is 9.93. Measured against sales, the shares trade at 1.7 times revenue. On price-to-sales that is 19.02% below the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.27. Daily returns over the trailing 7 years annualize to a volatility of 380.7%. Over the trailing twelve months the total return is +17.44%. Across 5 years the annualized return works out at +69.35%.

Growth & Income

The record shows no dividend for LOVE.TO.

The strongest complete calendar year on file is 2023 at +773.68%; the weakest is 2019 at −59.02%. Of the 7 complete calendar years on file, 3 finished higher. So far in 2026 the total return is +16.09%.

Peer Comparison

Cannara Biotech Inc. (LOVE.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cannara Biotech Inc. LOVE.TO CA$199.54M 18.4
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Cannara Biotech Inc. trades at a P/E of 18.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cannara Biotech Inc.

Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.

Visit website →